Bionano Genomics Inc BNGO

$1.16 +0.01 (0.87%)

Valuation

Market cap
16,074,000
Revenue TTM
$28,510,000
Net income TTM
$-26,400,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-92.60%
Debt to equity
0.00

Trading

Volume
149,200
Avg volume
1,170,416
Day's range
$1.12 – $1.20
Shares out
13,977,000
Stochastic %K
50%
Beta
1.73
Analysts
Moderate Buy
Price target
$5.00

Price

Company profile

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal...

Show more

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
858 888 7600
Website
https://bionano.com
Address
9540 Towne Centre Drive, Suite 100, San Diego, United States

Latest news

Stocktwits

TheBioPunkRevenger Nov 10, 4:04 AM
$BNGO Blood Advances (Nov 2026): OGM + targeted NGS classified 84% of 100 adult BCR::ABL1-negative B-ALL cases into distinct subtypes, cutting unclassified cases from 50% to 16%. OGM alone flagged BCR::ABL1-like in 26% (linked to higher MRD positivity). 97% concordance with FISH/SNP arrays while catching additional SVs standard methods missed. Run on Bionano Saphyr. Another independent academic data point that the map sees structural complexity conventional cytogenetics leave unresolved. Same layer already covered by live 81195. Useful for adoption narrative. Street still prices a kit. Literature keeps pricing a structural assay. https://ashpublications.org/bloodadvances/article/10/21/7299/570597/Comprehensive-genetic-characterization-of-adult
0 replies
MisterNessuno Nov 9, 4:25 PM
$BNGO May be 3$ by the EOY
0 replies
TheBioPunkRevenger Nov 7, 12:57 PM
$BNGO New paper (The Application of Clinical Genetics, 7 Nov 2026): Optical genome mapping of BCL11B::TLX3-rearranged pediatric T-ALL. In 53 pediatric T-ALL cases run on Bionano Saphyr, BCL11B::TLX3 (cryptic t(5;14)) was the most frequent recurrent structural rearrangement — 11/53 (20.8%). OGM detected the underlying translocation genome-wide and without prior targeting in every case, including those missed by conventional karyotyping. All confirmed by FISH. Same assay also resolved the co-occurring lesions (9p21.3 CDKN2A/B deletion in 9 of 11, plus other duplications and rearrangements). This is a real lab using the platform to characterize a known but often cryptic T-ALL driver and its genomic context in one run. Conventional methods (karyotype, FISH, CMA) miss pieces of this. OGM does not. Another data point in the heme stack showing diagnostic yield on live systems. Models still mostly price the old workflow.
1 replies
TheBioPunkRevenger Nov 6, 4:51 PM
$BNGO New paper: analytical superiority of OGM vs karyotyping in acute leukemia is clear. Specificity ~100%, sensitivity 95.6–96%, accuracy 97–98%. More reportable variants than karyotype + FISH. Additional findings that change classification or risk. Karyotyping only hangs on because of current turnaround time for a preliminary call. That is operational, not analytical. Optimized OGM pipelines are already faster in labs that treat it as the primary structural assay instead of running it in parallel with the old stack. It’s classic adoption. The paper is documenting the gap that remains. The technology has already cleared the performance bar. Heme OGM is live. Models are still pricing the lower-resolution method. That is the 15σ detachment. https://www.canjmedspec.com/article/172324-analytical-superiority-versus-turnaround-time-why-karyotyping-persists-amid-the-emergence-of-optical-genome-mapping-in-acute-leukemia-diagnostics
0 replies
TheBioPunkRevenger Nov 6, 4:40 PM
$BNGO Greenwood Genetic Center has run OGM clinically for nearly two years. Lab director Nikhil Sahajpal reports it solves ≥5% of rare-disease cases still undiagnosed after genome sequencing, exome, and microarray — one in twenty families who already ran the standard stack. Replace microarray with OGM in microarray + exome setups. Keep WGS first-line; use OGM as the reflex when negative. Added value is structural context (location, orientation, insertion) that microarray cannot provide. This is the constitutional layer (81354) delivering measurable yield in a real clinical lab, with a call to move OGM earlier in the workflow. Models still price mostly the heme kit. A lab that has implemented it is publicly quantifying the residual and telling others to use more of it. That is adoption. The 5% is the floor on the unsolved cases. The rest of the menu has not been asked yet. https://finance.biggo.com/news/f2727e1c22412f3a
0 replies
Yakko_Warner Nov 5, 9:47 PM
$BNGO I am still holding this for 2 years now just for the shits and giggles.
0 replies
PhilipDeezNutz Nov 5, 1:42 PM
$BNGO Cha Ching. I hope.
0 replies
Bigbraids Nov 4, 11:39 PM
$REEMF upon looking at the 3 month chart I’m concluding this selling is to keep the flag structure. 3 months ago $REEMF popped up to previous highs, it faded until the buyer stepped in at .76 a month later and drove it to 1.15 over the course of a week where the significant $1 level drove increased liquidity, and finally last week they moved it just above .9 and are again forcing the fade. My belief is these lower highs with three flags captured into one larger flag is their method for washing out week hands and delivering a clear inflection point around .8 which they’ll use as a spring board to rocket the price. Saw something very similar with $BNGO in 2020 where the professionals completed a sale of shelf shares creating a picture perfect bull flag that upon announcement shot the price from $.7 to $7 (the rest of the run was just retail a home killing time). Why all the trouble? To get their best price for a future share offering to pay for the full build out.
0 replies